This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
28 Feb 2011

TransPharma Announces Positive Results from Diabetes Patch Study

TransPharma Medical announced the successful completion of a Phase 1b trial of ViaDor-GLP1 agonist for the treatment of diabetes mellitus type II.

TransPharma Medical has reported positive results from a Phase Ib trial of its ViaDor-GLP1 agonist, which is being developed for the treatment of diabetes mellitus type II.

 

TransPharma Medical is a specialty pharmaceutical company focused on the development and commercialization of drug products utilizing a proprietary active transdermal drug delivery technology.Its ViaDor-GLP1 application involves the use of TransPharma's ViaDor drug-delivery system.

 

The single-dose, four-way cross-over study was designed to evaluate the pharmacokinetic profile, safety and tolerability of ViaDor-GLP1 agonist in diabetic patients by using TransPharma's extended-release film patch.

<

Related News